Vaccination Leads to Dramatic Decline in Outbreaks of Lumpy Skin Disease
News Feb 26, 2018 | Original Story from the European Food Safety Authority.
Outbreaks of lumpy skin disease (LSD) in the Balkan region fell dramatically by 95% from 7,483 in 2016 to 385 in 2017. The figures confirm that vaccination of cattle – recommended by EFSA in 2016 – is the most effective way to contain the disease.
A report published today by EFSA gives an update on the occurrence of LSD and the effectiveness of vaccination. It also analyses the risk factors for its spread in south-eastern Europe. The report is based on data collected by affected countries and those at risk.
However, Alessandro Broglia, a veterinarian at EFSA, warned: “Even if the number of outbreaks has decreased significantly, the disease has not been eliminated from the region yet and therefore we need to remain vigilant.”
In 2017 most of the outbreaks – 379 – were reported in areas of Albania where the vaccination programme had not yet been completed. Few outbreaks occurred elsewhere, with two in Greece and four in the former Yugoslav Republic of Macedonia.
One of the factors responsible for the spread of LSD is an increase in the number of insects that transmit the disease, as a result of warm temperatures.
Experts also concluded that in Greece the risk of infection is six times higher among farmed animals that have access to outdoor space than in those kept indoors. This is because the former group is more exposed to transmitting insects.
The cooperation and commitment of countries involved in the data collection was crucial for the report. EFSA used data provided by Albania, Bulgaria, Croatia, the former Yugoslav Republic of Macedonia, Greece, Kosovo, Montenegro, Serbia and Turkey.
This article has been republished from materials provided by the European Food Safety Authority. Note: material may have been edited for length and content. For further information, please contact the cited source.
Lumpy skin disease II. Data collection and analysis. 19 February 2018 EFSA Journal, doi:10.2903/j.efsa.2018.5176.
Patients with Parkinson’s disease are treated with levodopa, which is converted into dopamine, a neurotransmitter in the brain. In a new study, researchers show that gut bacteria can metabolize levodopa into dopamine. As dopamine cannot cross the blood-brain barrier, this makes the medication less effective – even in the presence of inhibitors that should prevent the conversion of levodopa.